Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Mitigating Deadlocks Triggered by SQLAlchemy's Implicit Autoflush: Architecture, Diagnostics, and Production Hardening

Mitigating Deadlocks Triggered by SQLAlchemy's Implicit Autoflush: Architecture, Diagnostics, and Production Hardening In high-concurrency relational database applications, deadlocks are notoriously difficult bugs to isolate. While application developers typically focus on explicit SQL locks—such as SELECT ... FOR UPDATE or explicit table locks—a subtle class of deadlocks stems directly from…

Deadlocks in high-concurrency relational database applications can be challenging to isolate and resolve. While developers often focus on explicit SQL locks like SELECT ... FOR UPDATE, a less apparent source of deadlocks originates from the ORM-level abstraction in SQLAlchemy. This article examines how SQLAlchemy's implicit autoflush mechanism can lead to deadlocks, presents a diagnostic tool using event listeners, and discusses production hardening strategies.

By default, SQLAlchemy's Session is configured with autoflush=True. Using the Unit of Work pattern, SQLAlchemy queues in-memory state changes (objects added, modified, or deleted) within the session's identity map. When a query is executed, SQLAlchemy assesses whether any pending in-memory mutations might affect the result. To preserve transactional consistency, SQLAlchemy automatically flushes pending operations to the database before executing the query.

Written by urgent.news from Dev.to's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at dev.to →

More in Health & Medicine

FDA Warns GLP-1s May Increase Risk of Sudden Blindness

An anonymous reader quotes a report from NBC News: The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden…

  • FDA warns GLP-1 drugs may increase risk of sudden blindness.
  • Study shows diabetes patients on semaglutide four times more likely to develop NAION.

More from Tuesday 10 November →